Back to first-pass browser

First-pass extracted concept

Selective MT1 receptor ligands

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This concept refers to ligands that selectively engage MT1 receptors to probe or modulate MT1-linked biology. In the review abstract, MT1 activation is associated mainly with REM sleep regulation.

Source 1DOIPubMed

Resources required

Use requires access to subtype-selective MT1 pharmacology and assays or models that can distinguish REM-related effects from other sleep outcomes.

Source 1DOIPubMed

What problem it solves

Selective MT1 ligands help avoid conflating MT1 effects with MT2 effects when the two receptor subtypes have distinct or opposing roles.

Source 1DOIPubMed

What it does not solve

The abstract does not show that MT1-selective ligands alone fully solve clinical sleep treatment challenges, and it does not name specific compounds or protocols.

Source 1DOIPubMed

Alternatives

The review contrasts selective subtype ligands with mixed MT1/MT2 ligands, melatonin, and non-selective MT1/MT2 agonists.

Source 1DOIPubMed

Evidence Snippets

Recent advancements using selective MT1/ MT2 receptor ligands and MT1/MT2 receptor knockout mice have suggested that the activation of the MT1 receptors are mainly implicated in the regulation of rapid eye movement (REM) sleep.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1anatomical localization summarysupports2019Source 1DOIPubMed

The review states that MT2 receptors are located in the reticular thalamus, whereas MT1 receptors are located in the locus coeruleus and lateral hypothalamus, consistent with distinct NREM and REM associations.

Claim 2circadian function summarysupports2019Source 1DOIPubMed

The review suggests that MT1, but not MT2, receptors appear to be involved in regulation of circadian rhythm.

Claim 3functional specializationsupports2019Source 1DOIPubMed

The review supports that MT1 receptor activation is mainly implicated in REM sleep regulation, whereas MT2 receptor activation selectively increases NREM sleep.

Claim 4therapeutic potential summarysupports2019Source 1DOIPubMed

The review suggests that selective MT2 agonists or partial agonists may have therapeutic potential for NREM-related sleep or anxiety disorders, whereas selective MT1 agonists or partial agonists may have therapeutic potential for REM-related sleep disorders.